To Evaluate the Efficacy and Safety of Tegileridine and Oliceridine Injections in the Treatment of Postoperative Pain

Inclusion criteria

• Accept elective laparoscopic combined thoracic surgery under general anesthesia, surgery time ≥ 1 h;
• 18 years old ≤ age ≤70 years old, regardless of gender;
• 18 kg/m2≤BMI≤30 kg/m2;
• American Society of Anesthesiologists (ASA) grade ⅰ-ⅲ;
• Within 4 hours after the end of surgery, NRS≥4 in the resting state at any time;
• Before starting trial-related activities, participants should voluntarily sign the informed consent form, fully understand the purpose and significance of this trial, and voluntarily abide by the trial procedures.

Exclusion criteria

• Patients with a previous history of difficult airway (obstructive sleep apnea syndrome), severe respiratory depression such as oxygen saturation < 90%, or a history of acute or severe bronchial asthma;
• Patients with a history of severe cardiovascular and cerebrovascular diseases (such as myocardial infarction or unstable angina pectoris, or severe arrhythmia such as atrioventricular block of degree Ⅱ or above, or ischemic stroke in NYHA class Ⅱ or above);
• Known or suspected gastric bowel obstruction, including paralytic ileus patients;
• Patients with allergy to opioids or any component of the trial drug;
• Subjects with previous psychiatric disorders (such as schizophrenia, depression, etc.) and cognitive impairment;
• With late-stage malignant tumors or with extensive metastasis of malignant tumor patients;
• Subjects with other somatic pain that may affect postoperative pain assessment;
• A history of drug, drug, and/or alcohol abuse within 1 year before randomization;
• Pregnant or lactating female subjects;
• Subjects with any other factor considered by the investigator to be ineligible for participation in the trial.